Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04924985 · ClinicalTrials.gov registry record · NA

Goal-directed CPR Using Cerebral Oximetry

A NA study of Ischemia and Reperfusion Injury, sponsored by NYU Langone Health.

Active
Registry status
NA
Development phase
150
Enrollment target
1
Study location

NCT04924985: Active NA study of Ischemia and Reperfusion Injury, sponsored by NYU Langone Health.

NCT04924985 is a NA study of Ischemia and Reperfusion Injury that is active but no longer recruiting, run by NYU Langone Health. The registered enrollment target is 150 participants, below the 475-participant average among 11 other Ischemia trials with a reported enrollment target (68% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04924985, a NA study of Ischemia and Reperfusion Injury, is active but no longer recruiting, sponsored by NYU Langone Health.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
150 participants
Enrollment target
1
Study location

Study Summary

The proposed study is a single-center, randomized controlled pilot trial of adults who suffer in-hospital cardiac arrests. Using cerebral oxygenation and end-tidal carbon dioxide physiological targets to predict survival and neurological outcome, the impact of physiological-feedback CPR will be assessed. 150 adult patients who have a cardiac arrest event at NYU Tisch Hospital will be randomized to one of two treatment groups: (1) Physiological-Feedback CPR or (2) Non-Physiological (Audiovisual) Feedback CPR.

Interventions

  • OTHER Non-Physiological Feedback CPR
  • OTHER Physiological Feedback CPR

Study Locations (1)

New York

  • NYU Langone Health - New York

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2022-02-11
Est. Completion 2025-07-31
Phase NA
NYU Langone Health

1,164 total trials

What the registry record for NCT04924985 still lists

NCT04924985 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 475-participant average among 11 other Ischemia trials with a reported enrollment target (68% lower).

The record links to 2 conditions, with Ischemia appearing as the primary indexed condition, and to 2 interventions - of which Non-Physiological Feedback CPR is the first listed.

NCT04924985 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT04924985 about?

NCT04924985 is a clinical study titled "Goal-directed CPR Using Cerebral Oximetry". The proposed study is a single-center, randomized controlled pilot trial of adults who suffer in-hospital cardiac arrests. Using cerebral oxygenation and end-tidal carbon dioxide physiological targets to predict survival and neurological outcome, the impact of physiological-feedback CPR will be asse...

What is the current status of trial NCT04924985?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 150 participants. The study started on 2022-02-11. Estimated completion is 2025-07-31.

What conditions does trial NCT04924985 study?

This clinical trial studies the following conditions: Ischemia, Reperfusion Injury.

What interventions are being tested in trial NCT04924985?

The interventions under investigation include: Non-Physiological Feedback CPR (OTHER), Physiological Feedback CPR (OTHER).

Who is sponsoring clinical trial NCT04924985?

This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04924985 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Ischemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04924985's enrollment target sits among peer trials

150 9th of 11 higher than 3 of 11 other Ischemia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Ischemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00412594 · 150 participants · Phase 2

    Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia

  • NCT01484730 · 150 participants

    A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion

  • NCT01985919 · 150 participants

    Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples

  • NCT02016248 · 150 participants · NA

    SBRT Boost for Unfavorable Prostate Cancer'

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04924985, the US trial registry maintained by the National Library of Medicine. NCT04924985 (mid enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.